Last reviewed 2026-05-15 · How we verify

A zoster mRNA vaccine SYS6017

SYS6017 is an mRNA vaccine that encodes varicella-zoster virus (VZV) antigens to stimulate adaptive immune responses against herpes zoster.

SYS6017 is an mRNA vaccine that encodes varicella-zoster virus (VZV) antigens to stimulate adaptive immune responses against herpes zoster. Used for Prevention of herpes zoster (shingles) in adults.

At a glance

Mechanism of action

The vaccine delivers mRNA encoding immunogenic VZV proteins, which are translated intracellularly to present viral epitopes to the immune system. This triggers both CD8+ T-cell and antibody responses to prevent or reduce the severity of herpes zoster (shingles) infection. The mRNA-based platform allows rapid manufacturing and potentially improved immunogenicity compared to traditional inactivated vaccines.

Approved indications

• Prevention of herpes zoster (shingles) in adults

Common side effects

• Injection site reactions (pain, erythema, swelling)
• Fatigue
• Myalgia
• Headache
• Fever

Key clinical trials

• Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above (PHASE2)
• Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• A zoster mRNA vaccine SYS6017 CI brief — competitive landscape report
• A zoster mRNA vaccine SYS6017 updates RSS · CI watch RSS
• CSPC Megalith Biopharmaceutical Co.,Ltd. portfolio CI